The Surgical Robotics Market in 2026

As of 2026, the surgical robotics market is characterised by: Intuitive Surgical maintaining its dominant position in soft tissue surgery with the da Vinci platform (5,000+ installed globally), Stryker (Mako) and Zimmer Biomet (Rosa) competing actively in orthopaedic and joint replacement robotics, Medtronic (Hugo) and Johnson & Johnson (Ottava) entering the general surgery soft tissue robotics market, Smith+Nephew and Globus Medical competing in spine robotics, and a wave of emerging companies (CMR Surgical, Avatera, Distalmotion, Think Surgical) in various specialties. The transition to competitive multi-vendor robotics markets is accelerating adoption as hospital procurement teams have more price competition and choice.

Orthopaedic Robotics: The Fastest-Growing Segment

Orthopaedic robotic surgical systems — used for total knee, total hip, and partial knee replacement — are currently the fastest-growing surgical robotics segment. Stryker's Mako platform and Zimmer Biomet's Rosa are the market leaders. These systems improve implant positioning accuracy and patient outcomes compared to conventional surgical technique. For Turkish orthopaedic implant manufacturers, this trend is critically important: robots are system-integrated — if your implant is not in the robot's implant library, it may be excluded from robotic procedures. Turkish implant manufacturers should assess whether their implant designs can be validated for integration with leading robotic systems.

General Surgery Robotics: The Next Mass Market

Intuitive Surgical's da Vinci has dominated general surgery robotics since 2000, but the market is opening up. Medtronic's Hugo system is receiving regulatory clearances globally; J&J's Ottava platform is in late-stage development; CMR Surgical's Versius is expanding into new markets. The introduction of competitive platforms is expected to significantly reduce the cost of soft tissue robotics, dramatically expanding the total addressable market from major academic and private hospitals to mid-sized regional hospitals. This democratisation of robotic surgery is projected to accelerate from 2026 onwards.

Key Components in Surgical Robotics

Surgical robotic systems are complex assemblies of mechanical, electronic, and software components. Key components with manufacturing supply chain opportunities include: precision mechanical arms and joints (high-tolerance machined components), electrosurgical generators and energy delivery systems, endoscopic instruments (dissectors, graspers, needle drivers, clip appliers), draping and sterile barrier systems, imaging systems (3D endoscopes, fluorescence imaging), and training simulators. Turkish precision manufacturing companies — with established medical device manufacturing quality systems — can potentially supply component and subassembly categories to robotic system OEMs.

Regulatory Pathway for Surgical Robotic Systems

Surgical robotic systems are typically classified as Class IIb (EU MDR) or Class II (FDA 510(k)) for most general and orthopaedic applications, with Class III for specific high-risk applications. Clinical evidence requirements are significant: surgical robotic system manufacturers must demonstrate safety and performance through bench testing, cadaveric studies, and clinical investigations. The software component of surgical robotic systems is typically Class C under IEC 62304, requiring the most rigorous software life cycle documentation. Post-market clinical follow-up (PMCF) with outcome data from robotically-assisted procedures is an increasing regulatory expectation.

Implications for Turkish Medical Device Manufacturers

For Turkish medical device manufacturers, the surgical robotics trend creates several strategic considerations: (1) Implant-robot compatibility: Turkish orthopaedic and spine implant manufacturers should monitor which robotic systems are gaining adoption in their target markets and assess compatibility/integration strategies, (2) Instrument manufacturing: robotic-compatible instruments (smaller profiles, specific material requirements for robotic arm interfaces) represent a potential product line extension for Turkish surgical instrument manufacturers, (3) Draping systems: robotic system draping (sterile barriers for robotic arms) is a significant consumable category for Turkish disposables manufacturers to consider, (4) Capital investment context: hospitals investing heavily in robotic platforms will have different capital budget availability for conventional device procurement — understanding this dynamic is important for sales forecasting.

Conclusion

Surgical robotics is not a distant future trend — it is actively reshaping hospital capital investment, clinical preferences, and device procurement specifications today. Turkish medical device manufacturers who engage proactively with the robotic surgery ecosystem — through compatibility assessment, component supply opportunities, or distribution partnerships — will be better positioned as the robotics revolution moves from major teaching hospitals to the broader global market.